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Comprehensive genomic profiling in
routine clinical practice leads to a low rate
of benefit from genotype-directed therapy
Talal Hilal1, Mary Nakazawa2, Jacob Hodskins3, John L. Villano3, Aju Mathew3, Guarav Goel4, Lars Wagner3,
Susanne M. Arnold3, Philip DeSimone3, Lowell B. Anthony3 and Peter J. Hosein5*

Abstract
Background: Describe a single-center real-world experience with comprehensive genomic profiling (CGP)
to identify genotype directed therapy (GDT) options for patients with malignancies refractory to standard
treatment options.
Methods: Patients who had CGP by a CLIA-certified laboratory between November 2012 and December 2015
were included. The medical records were analyzed retrospectively after Institutional Review Board (IRB) approval.
The treating oncologist made the decision to obtain the assay to provide potential therapeutic options. The
objectives of this study were to determine the proportion of patients who benefited from GDT, and to identify
barriers to receiving GDT.
Results: A total of 125 pediatric and adult patients with a histologically confirmed diagnosis of malignancy were
included. Among these, 106 samples were from adult patients, and 19 samples were from pediatric patients. The
median age was 54 years for adults. The majority had stage IV malignancy (53%) and were pretreated with 2–3
lines of therapy (45%). The median age was 8 years for pediatric patients. The majority had brain tumors (47%)
and had received none or 1 line of therapy (58%) when the profiling was requested. A total of 111 (92%) patients
had genomic alterations and were candidates for GDT either via on/off-label use or a clinical trial (phase 1 through 3).
Fifteen patients (12%) received GDT based on these results including two patients who were referred for genomically
matched phase 1 clinical trials. Three patients (2%) derived benefit from their GDT that ranged from 2 to 6 months
of stable disease.
Conclusions: CGP revealed potential treatment options in the majority of patients profiled. However, multiple
barriers to therapy were identified, and only a small minority of the patients derived benefit from GDT.
Keywords: Genotype-directed therapy, Profiling, Genomics, Cancer therapeutics

Background
Carcinogenesis is a multi-step process propelled by genomic alterations that leads to dysregulation of signaling
pathways, which consequently gives rise to qualities that
enable tumor proliferation and dissemination [1]. Our
understanding of the molecular processes underlying
malignancies has translated to targeted therapies, which
have transformed the clinical management of some
* Correspondence: phosein@med.miami.edu
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cancers. Indeed, the landscape of systemic therapy in
certain malignancies is evolving from its dependence on
nonselective cytotoxic therapies to one that includes the
utilization of selective inhibitors [2]. Since the first
breakthrough in molecular targeted therapy with imatinib, whose action against BCR-ABL kinase produced
robust responses in chronic myeloid leukemia (CML)
[3], various oncogenic drivers of the proliferative phenotype have been uncovered and translated into therapies.
The use of trastuzumab, a humanized monoclonal antibody against human epidermal growth factor receptor 2
(HER2) is standard of care for HER2 overexpressed
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breast cancers [4] and more recently approved for HER2
overexpressed gastric cancer, which represents the first
targeted therapy in this malignancy [5]. While these
well-studied and validated alterations are routinely targeted in clinical practice, patients with other alterations
in frequently mutated pathways may also benefit from
targeted therapies.
Today, comprehensive genomic profiling (CGP) of tumors can provide insight into clinically relevant genetic
alterations (CRGAs), with goals of guiding clinical
decision-making and augmenting therapeutic options.
The accessibility of this technology facilitates the shift
towards precision medicine by identifying specific patient populations that are most likely to derive benefit
from a particular therapy. However, the proportion of
patients that end up receiving genotype-directed therapy
(GDT) represents the minority of total patients profiled,
despite a large proportion having actionable genetic alterations [6]. In addition, only a small fraction of patients profiled in such studies derive benefit from the
treatment [7]. The reasons for the marked divergence
in patients profiled to have actionable mutations and
those that ultimately receive GDT have not been systematically studied.
Herein we present a single institution study of the outcomes of CGP in the clinical management for these patients, with focus on exploring the reasons for which
patients with actionable mutations did not receive GDT.
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sequences the coding region of 236 cancer-related genes
plus introns from 19 genes often rearranged or altered
in cancer to a typical median depth of coverage of
greater than 250X. Sample requirements are ≥40 μm
tissue, of which a minimum of 20% is of malignant origin, on 8 to 10 unstained slides or in a formalin-fixed
paraffin-embedded block. The sensitivity of the test is
reported at >99% for base substitutions, >97% for indels,
>95% for copy number alterations, and >90% for rearrangements. The specificity is reported at >99% for all
classes of genomic alterations [9].
Report interpretation

The Foundation Medicine report provided a list of
CRGAs with suggested treatment options that were onlabel, off-label, or both. In addition, a list of phase 1–3
trials that may be recruiting for patients with specific
CRGAs was provided. The treating oncologist made
his/her own interpretations to identify treatments based
on the report. Patients with CRGAs with on-label options have either received the recommended, on-label
therapy, or will be receiving it at which point the report
was saved for potential future use. Patients with CRGAs
without on-label options were either referred for a clinical trial that was selected by the treating oncologist, or
received an off-label therapy that was suggested by the
report. If the options listed in the report were deemed
unlikely to be effective by the treating oncologist, an alternative therapy was used.

Methods
Study population/design

Clinical endpoints

This was a retrospective, single-center, observational
study that reviewed the medical records of adult (> or
equal to 18 years of age) and pediatric (<18 years of age)
patients with a histologically confirmed diagnosis of malignancy. All patients who had CGP between November
2012 and December 2015 at the University of Kentucky
were included. Data cut-off was in June 2016. No restrictions on tumor histology, disease stage, subsequent
or previous treatment, or performance status were imposed. Malignant tumors were tested with a commercially available CGP assay performed by Foundation
Medicine. The decision to obtain the assay for a particular patient was at the discretion of the primary
physician. Archived tissue from patients’ diagnostic biopsies or surgical resection was used for testing. The
Institutional Review Board (IRB) of the University of
Kentucky approved the study.

The primary objective was to identify the barriers to receiving GDT. The secondary objectives were to determine the percentage of patients with CRGAs, and the
proportion of patients who benefitted from GDT either
by having a response to therapy defined by RECIST v.1.1
criteria or disease stabilization. Patients were considered
to have received GDT only when the test result identified genetic alterations to which an off-label therapy or a
clinical trial could be offered. Patients with a previously
established genomic alteration discovered on routine
clinical testing for which a standard of care targeted
agent was available (e.g. trastuzumab for HER2 positive
breast cancer) were not counted to have received GDT
based on the results of the test.

Genomic testing

The methodology used in next-generation sequencing
has been well-described in previous publications and
replicated in the majority of commercial CGP platforms
[8]. The Foundation Medicine platform simultaneously

Results
Patient characteristics

Baseline demographics are displayed in Table 1. The
median age was 54 years for adults, with equal gender
distribution. The majority had stage IV malignancy
(53%) followed by stage III (25%). Most patients were
pretreated with 2–3 lines of therapy (45%); 38% received
one or no prior lines of therapy. The median age was
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Table 1 Baseline characteristics and demographic information
Variable
Age at diagnosis (years)

Sex

Stage (TNM)

Prior lines of systemic therapies

Adult cohort n = 106

Pediatric cohort n = 19

Median

54

8

Range

21–93

2–17

Female

54 (51%)

9 (47%)

Male

52 (49%)

10 (53%)

I

7 (7%)

4 (21%)

II

13 (12%)

-

III

26 (25%)

-

IV

56 (53%)

6 (32%)

Other (Non-TNM)

-

9 (47%)

Unknown

4 (3%)

-

0–1

41 (38%)

11 (58%)

2–3

48 (45%)

5 (26%)

4 or more
Prior standard-of-care targeted therapy

8 years for pediatric patients, with equal gender distribution. The majority had either brain tumors (47%) or
stage IV malignancy (32%). Most patients had received
none or 1 line of therapy (58%) when the profiling was
requested. Median follow-up was 12.9 months (range,
5.6–43.3 months).
One hundred and twenty-five patient tumor samples
were submitted for testing. Among these, 106 tumor
samples were from adult patients, and 19 tumor samples
were from pediatric patients (Table 2). In adults, the
most common tumor histology evaluated were sarcomas (n = 24), followed by non-small cell lung cancer
(NSCLC) (n = 17), and breast and colorectal (n = 11
each). In pediatric patients, the most common tumors
evaluated were primary brain tumors (n = 9).

18 (17%)

3 (16%)

11 (10%)

-

available, but there were 11 (65%) with a genomic alteration for which an off-label option was available (see
Table 3).
Genomic alterations were detected across a range of
functionally relevant molecular pathways. Cell cycle
regulation genes were the most frequently altered
pathways with mutations, amplifications or deletions
present in 37% of tumors. A mutation in the p53 gene
was the most frequently identified single gene alteration, found in 48% of tested samples. Alterations in
the phosphatidylinositol 3-kinase (PI3K)-AKT pathway
and the mitogen-activated protein kinase (MAPK)
pathway were identified in 21% and 28% of samples,
respectively (Fig. 1).
Treatment options and response

Clinically relevant genetic alterations

Four patients (2 adults and 2 pediatric patients) had insufficient tumor DNA in the specimens submitted to
perform profiling. In adults, at least one genomic alteration was identified in 97 tumor samples (93%) all of
which had phase 1 clinical trial options and were therefore defined as CRGAs. Twenty-five adult patients (24%)
had genomic alterations for which an on-label, FDAapproved option was available – most of these alterations were already known prior to CGP because of
standard-of-care biomarker testing (e.g. RAS mutation
testing in colorectal cancer). Seventy-eight adult patients
(74%) had genomic alterations for which an off-label
option was available. In pediatric patients, at least one
genomic alteration was identified in 14 tumor samples
(82%) all of which had phase 1 clinical trial options.
There were no pediatric patients with genomic alterations for which an on-label, FDA-approved option was

Out of the total of 121 patients with valid CGP results,
111 (92%) had CRGAs and were candidates for GDT
either via on/off-label use or a clinical trial (phase 1
through 3). Fifteen patients (12%) received GDT based
on these results including two patients who were referred for genomically-matched phase 1 clinical trials.
Three patients (2%) derived benefit from their GDT that
ranged from 2 to 6 months of stable disease; two patients in the adult population with lung adenocarcinoma
and gastric cancer, and one of patient in the pediatric
population with anaplastic astrocytoma (Table 4). Out of
the total of 62 patients with stage IV malignancy, this
meant 24% received GDT, and 5% derived benefit.
Barriers to genotype-directed therapy

Most patients were not offered GDT based on the assay
report (Table 5). The most common reasons were ongoing treatment with standard-of-care therapy, or off-
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Table 2 Histologies of tumors profiled in adult and pediatric
patients

Table 2 Histologies of tumors profiled in adult and pediatric
patients (Continued)

Adult (n = 106)

Sarcoma

Head and Neck

Giant cell tumor

1

Salivary gland

1

Osteosarcoma

1

HNSCCa

2

Rhabdomyosarcoma

1

Thyroid

2

Ewing

3

Esthesioneuroblastoma

1

NOS/Other

1

Lung
NSCLC

17

SCLC

1

Neuroendocrine

1

Breast

11

Esophageal

2

Gastric

3

Hepatobiliary
Hepatocellular carcinoma

1

Cholangiocarcinoma

8

Gallbladder Carcinoma

2

Pancreatic adenocarcinoma

4

Colorectal

11

Neuroendocrine - GI

2

Adrenocortical carcinoma

3

Urothelial/Bladder Carcinoma

1

Ovarian carcinoma

1

Uterus carcinoma

1

Neuroendocrine - GU

1

Melanoma

1

Melanoma

1

TOTAL

19

label therapy/clinical trial participation not suggested
by assay report (n = 42, 40%). In other words, testing
in this population was done early in the disease treatment course and the results were not applicable at the
time the results were available, or the results deemed
unlikely to be effective by the treating oncologist leading to off-label therapy or clinical trial participation
which would have taken place regardless of whether
CGP was ordered. Less common reasons were deteriorating/poor performance status (n = 25, 23%), and
disease in remission with no indication for therapy
(n = 18, 17%). Testing in this population was done either too late in the treatment course to be of clinical
utility, or done on patients with early stage cancers
who underwent curative intent therapy, respectively.
Other reasons for not receiving GDT included no
actionable mutations (n = 11, 10%), or rapid disease
progression (n = 5, 5%).

Unknown primary

5

Discussion
The concept of individualizing a patient’s treatment
based on a specific alteration in their tumor is attractive
to oncologists and patients alike. This approach is
already validated in a number of malignancies and there
are now many FDA-approved therapies that require testing for a predictive biomarker [10, 11]. In these cases,
where there is a validated drug-biomarker pair, the

TOTAL

106

Table 3 Results of profiling

Sarcoma
Osteosarcoma

3

GIST

1

Leiomyosarcoma

2

Liposarcoma

3

NOS/Other

15

Pediatric (n = 19)

Variable

Adult cohort Pediatric cohort
n = 106
n = 19

Brain tumors
Juvenile pilocytic astrocytoma

1

Oligodendroglioma

1

Ependymoma

2

Anaplastic astrocytoma

2

GBM

1

Atypical teratoid/rhabdoid

2

Neuroblastoma

2

Valid results

104 (98%)

17 (90%)

Adult cohort Pediatric cohort
n = 104
n = 17
On-label options only

3 (3%)

0

Off-label options only

55 (53%)

11 (65%)

Both on- and off- label options
Clinical Trial options

22 (21%)

0

96 (92%)

14 (82%)

Phase II 76 (73%)

11 (65%)

Phase III 11 (11%)

0

Phase I

Hilal et al. BMC Cancer (2017) 17:602
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Fig. 1 Proportion of samples with alterations by class of molecular pathway

outcome with biomarker-guided therapy is usually very
rewarding, leading to improvement in survival. The success of this approach in some situations has generated
tremendous enthusiasm for splitting tumors into groups
based on driver alterations and treating based on these
results. Testing for driver genomic alterations has
become routine clinical practice with the proliferation
of a number of commercially available platforms for
analyzing patients’ tumor specimens in an attempt to

uncover vulnerabilities in the tumor that may be susceptible to new targeted therapies. However, based on the
evidence we present here, as well as many other studies,
it appears that the widespread uptake of genomic profiling is ahead of the evidence supporting its benefit.
The rate of benefit from GDT in our study, defined as
stable disease or a partial response to therapy was 5% in
patients with stage IV malignancies. This low proportion
is in the range of what has been reported in other series.

Table 4 GDT utilized based on NGS results (n = 15)
Patient Tumor Type

Targeted Genetic Alterations

Therapy

Duration of benefit Best Response
(months)
after GDT

1

Cholangiocarcinoma

BRAFV471F, EGFR T790 M

Sorafenib

0

PD

2

Breast cancer, recurrence

AKT3 amplification, PIK3R1 F456_E458del, Everolimus
PTEN loss exon 3

0

PD

3

NSCLC, squamous with sarcomatous
features

KRAS G13D

Trametinib

0

PD

4

Head and neck squamous cell
carcinoma

EGFR amplification

Cetuximab

0

PD

5

NSCLC, adenocarcinoma

NRAS Q61K

Trametinib

5

SD

6

Breast cancer

PIK3R1 K448_Y452del

Everolimus

0

PD

7

Osteosarcoma

CCND3 amplification, CDK4
amplification

Palbociclib

0

PD

8

Anaplastic astrocytoma

BRAFV600E (HGF amplification)

Vemurafenib

6

SD

9

Large cell neuroendocrine carcinoma

PTEN N323 fs*2

Everolimus

0

PD

10

Cholangiocarcinoma

IDH2 R172K

AG-881 (IDH inhibitor)

0

PD

11

Esophageal carcinoma

PIK3CA R88Q, STK11 loss

Everolimus

0

PD

12

Gastric adenocarcinoma

FLT3 amplification

Sorafenib

2

SD

13

NSCLC, squamous

HGF amplification

Crizotinib

0

PD

14

GE junction adenocarcinoma

VEGFA amplification

Sorafenib

0

PD

15

Adrenal cortical cancer

TP53 H179R

AZD1775
0
(WEE1 kinase inhibitor)

PD

Hilal et al. BMC Cancer (2017) 17:602
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Table 5 Reasons for not receiving GDT (n = 106)
Reason

Frequency (%)

No actionable mutations

11 (10%)

Disease in remission/no indication for therapy

18 (17%)

Patient still receiving standard of care/off-label option or clinical trial not suggested by F1 report

42 (40%)

Patient is no longer a candidate for therapy due to deteriorating or poor performance status

25 (23%)

Physician preference for no GDT specifically because of rapid disease

5 (5%)

On/off label GDT recommended or clinical trial available locally but patient declined

3 (3%)

Patient offered clinical trial but unable to travel/insurance decline

2 (2%)

Table 6 shows a summary of similar real-world singlecenter experience with GDT in routine clinical practice.
These studies all showed a high rate of potentially actionable alterations but a low rate of patients receiving
matched therapy and an even lower rate of patients who
derive benefit from this process [7, 12–17]. If one uses
all patients entering the testing algorithm who are
hoping for a “home-run” targeted therapy as the denominator, the proportion of patients who do achieve
some disease control from therapy is between 2 to 8%
across multiple studies.
Apart from the institutional series described above, the
prospective SHIVA trial is a study that is often cited as
an example of the limitations of GDT [18]. This study
randomized patients who had one of a defined set of
alterations to received genomically matched targeted
therapy versus investigator’s choice chemotherapy. There
was no difference in progression-free survival in the patients who received matched therapy versus those who
received standard chemotherapy. Despite this apparent
negative result, this study was by no means definitive
and the main limitation was that the targeted drugs used
were not validated against the purported targets and in a
heavily pretreated population; the weak drug-target pairs
were unlikely to succeed [19].

Contrast this study to the study of erlotinib versus
chemotherapy for the first-line treatment of patients
with lung cancer harboring an EGFR activating mutation. This study showed remarkable superiority of erlotinib in this setting with a hazard ratio for survival of 0.16
(95% CI 0.1 to 0.26) [20]. This clearly illustrates the
principle that a validated drug-biomarker pair can lead
to excellent outcomes. It also highlights the inherent
complexity of tumors and the wide variety of genomic
alterations that introduce bias in treatment selection.
Many cancers do not have clear driver mutations, and
targeting a random genomic alteration will have no effect of the natural history of the disease.
More recently, the ProfiLER trial, a multi-institutional
prospective study from France, has reported data on
1826 patients. Approximately half (51%) had at least one
actionable mutation, and 35% were deemed to be eligible
for matched therapy when utilizing a molecular tumor
board. Among those, 6% initiated a recommended
matched therapy. The rate of benefit, which included
complete response, partial response, and stable disease,
was 2.4% of the total population (44% of those who initiated therapy) [21].
Our study has a number of important limitations. This
was not a prospective study and the implementation of

Table 6 Single institution studies examining genotype-directed therapy
Study

Number of
Subjects

Design

Rate of Actionable
Alterations

Rate of Matched
Therapy

Rate of
Benefita

Current study

126

Retrospective, single institution

92%

12%

2%

Vanderbilt [12]

103

Retrospective, single institution

83%

21%

8%

First MDACC [13]

1144

Prospective, phase 1 study

40%

18%

5%

UCSD [14]

34

Prospective, single institution, molecular tumor board

94%

35%

21%

Cornell [7]

97

Prospective, single institution

94%

5%

2%

Rutgers [15]

92

Prospective, single institution, molecular tumor board

96%

35%

NR

Second MDACCb [16]

339

Prospective, single institution

94%

32%

NR

University of Michigan [17]

500

NR

72%

5–11%

NR

NR not reported
a
Benefit defined as partial response (PR) + stable disease (SD)
b
Supported by a grant from Foundation Medicine
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GDT was physician-dependent and not standardized.
Many institutions now have molecular tumor boards
that systematically review profiling results and attempt
to match patients to clinical trials or the best available
treatment based on the results. Even in a supervised setting like this, the rate of matched therapy is still low.
The benefit derived from matched therapy, however,
may be higher as shown in one single-center experience
[14]. This is likely due to a more scrutinized approach
in interpreting the genomic data, and selecting the
appropriate patients whose tumors have shown a more
indolent biology (e.g. most patients in the ProfiLER
study who initiated GDT had gynecologic, colorectal
and breast malignancies; many known to behave in indolent manner).
Another weakness of our study was the inconsistency
in the timing of sending CGP. In some cases, testing was
requested early in the disease course and the results
were available while patients were still on standard-ofcare therapy or in remission. Presumably the testing results could be retrieved and acted upon if the patients
developed disease progression. However, the molecular
alterations at the time of progression may evolve and the
results of prior testing may no longer be reliable [22].
On the other hand, many patients had testing done very
late in their disease course and did not have the time to
have the results implemented. In general, we found that
patients who had rapid disease progression or poor performance status due to their malignancy (28% of our
cohort) did not have the opportunity to benefit from
the results of GDT and testing these patients did not
alter the outcome.
Lack of easy access to phase 1 clinical trials was also a
major barrier to GDT in our study – our center had few
available phase 1 trials at the time of this study. This led
to many patients receiving off-label therapy that was felt
to be efficacious at the discretion of the treating oncologist. Community oncology practices alike generally have
limited access to phase 1 therapeutic trials making our
experience reflective of the wider oncology practice.
However, the use of “off-label” GDT should not be the
norm since the activity of a drug targeting a particular
mutation is different for distinct tumor types (e.g. BRAF
inhibitors are very efficacious in BRAFV600E mutated
melanoma, but lack the same activity in BRAFV600E
mutated colon cancer).
So how do we move forward? Based on the evidence
we provide in our study and the other studies cited here,
a haphazard approach to CGP is very unlikely to help
patients. Tumor profiling should be done in a deliberate
way with systematic analysis of the results to guide patients into appropriate clinical trials, avoiding those who
are unlikely to benefit, such as patients with rapid disease progression or those in whom standard therapy is
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being successfully applied. This means that the optimal
time for requesting CGP may differ with distinct histologically defined tumor types. The aspect of biologic
complexity of tumors and intratumor heterogeneity
should also be considered, as these patients are unlikely
to benefit from a targeted approach unless the target is a
driver alteration. Moreover, the financial burden of CGP
on both the healthcare economy and individual patients
should be kept in mind. In one study of 209 patients in
a community practice, the total cost was reported at
$1.21 million, and 17% of patients were responsible for
the full cost after exhausting financial coverage and
support options [23].
The ongoing NCI-MATCH trial is an example of a
basket trial that is meticulously approaching this problem. The drug-biomarker pairs have passed a minimum
bar of validation and this study will provide further evidence as to whether some of the pairs will in fact benefit
patients. The ASCO-TAPUR trial is another example
that utilizes a molecular tumor board composed on a
group of experts convened by ASCO that provide an
informed decision regarding the proposed treatment. On
the other hand, SPECTAcolor (Screening Patients for
Efficient Clinical Trial Access in advanced colorectal
cancer) is an example of a large European collaboration
that aims to screen patients with colorectal cancer to
improve access to molecularly defined clinical trials [24].

Conclusions
In this study, the routine use of CGP in clinical practice
was associated with minimal benefit to patients in terms
of disease control. Furthermore, we were able to identify
various barriers to implementation of GDT that should
be taken into consideration before requesting CGP on
tumor specimens. Until the results of prospective trials
are reported, it will be difficult to curb the runaway train
that is the routine clinical use of CGP. However, given
the available data we recommend against routine CGP
outside the context of a prospective precision medicine
program or well-designed clinical trials.
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